US2006159677A1PendingUtilityA1

Tumour necrosis factor peptide binding antibodies

67
Assignee: PEPTECH LTDPriority: Aug 7, 1989Filed: Mar 7, 2006Published: Jul 20, 2006
Est. expiryAug 7, 2009(expired)· nominal 20-yr term from priority
Inventors:Deborah RathjenRoger Aston
C07K 2317/92C07K 2317/622A61K 38/00C07K 16/241A61K 47/6813A61K 47/68C07K 2317/21A61K 2039/505C07K 2317/24C07K 2317/73C07K 2317/56C07K 2319/00C07K 2317/75
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are isolated antibodies or fragments thereof which bind a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68 (peptide 308) of mature human TNF-α. The antibodies and fragments thereof may be used to identify antibodies capable of binding in the region of mature human TNF-α of amino acid resides 54-68. Antibodies or fragments thereof which bind particular regions of mature human TNF-α are shown to elicit particular biological activities dependent upon the particular region wherein binding occurs.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or fragment thereof which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         2 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a monoclonal antibody.  
     
     
         3 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a chimeric antibody.  
     
     
         4 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a humanized antibody.  
     
     
         5 . An antibody or fragment thereof according to  claim 1 , wherein the antibody is a human antibody.  
     
     
         6 . A composition comprising an isolated antibody or fragment thereof which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         7 . A composition according to  claim 6 , wherein the antibody is a monoclonal antibody.  
     
     
         8 . A composition according to  claim 6 , wherein the antibody is a chimeric antibody.  
     
     
         9 . A composition according to  claim 6 , wherein the antibody is a humanized antibody.  
     
     
         10 . A composition according to  claim 6 , wherein the antibody is a human antibody.  
     
     
         11 . An isolated single chain antibody which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         12 . An antibody according to  claim 11 , wherein the antibody is a monoclonal antibody.  
     
     
         13 . An antibody according to  claim 11 , wherein the antibody is a chimeric antibody.  
     
     
         14 . An antibody according to  claim 11 , wherein the antibody is a humanized antibody.  
     
     
         15 . An antibody according to  claim 11 , wherein the antibody is a human antibody.  
     
     
         16 . A composition comprising an isolated single chain antibody which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         17 . A composition according to  claim 16 , wherein the antibody is a monoclonal antibody.  
     
     
         18 . A composition according to  claim 16 , wherein the antibody is a chimeric antibody.  
     
     
         19 . A composition according to  claim 16 , wherein the antibody is a humanized antibody.  
     
     
         20 . A composition according to  claim 16 , wherein the antibody is a human antibody.  
     
     
         21 . An isolated single domain antibody or fragment thereof which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         22 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a monoclonal antibody.  
     
     
         23 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a chimeric antibody.  
     
     
         24 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a humanized antibody.  
     
     
         25 . An antibody or fragment thereof according to  claim 21 , wherein the antibody is a human antibody.  
     
     
         26 . A composition comprising an isolated antibody or fragment thereof which binds a peptide consisting of residues Gly 54 -Leu 55 -Tyr 56 -Leu 57 -Ile 58 -Tyr 59 -Ser 60 -Gln 61 -Val 62 -Leu 63 -Phe 64 -Lys 65 -Gly 66 -Gln 67 -Gly 68  (peptide 308) of mature human TNF-α.  
     
     
         27 . A composition according to  claim 26 , wherein the antibody is a monoclonal antibody.  
     
     
         28 . A composition according to  claim 26 , wherein the antibody is a chimeric antibody.  
     
     
         29 . A composition according to  claim 26 , wherein the antibody is a humanized antibody.  
     
     
         30 . A composition according to  claim 26 , wherein the antibody is a human antibody.

Join the waitlist — get patent alerts

Track US2006159677A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.